Farid Chekani, PhD

  • 2Articles
  • 17.6KReads1
  • 2020–2023Active
  • 12Collaborators
  • 5Citations2

About

Farid Chekani, PhD, is affiliated with Merck & Co., Inc. in Kenilworth, New Jersey. Chekani has published research on schizophrenia and schizoaffective disorders, focusing on topics such as antipsychotic-related weight gain and its impact on treatment adherence, as well as real-world treatment outcomes in schizophrenia patients. Contributions have appeared in Psychiatrist.com between 2020 and 2023. Frequent co-authors include Rezaul Khandker, Anna Roberts, and Anthony J. Perkins.

Publications

PCC
Antipsychotic-Related Weight Gain and Adherence
Original Research

Antipsychotic-Related Weight Gain and Adherence

March 9, 2023

A considerable amount of weight gain was observed among antipsychotic-naive users, even among those whose treatment was considered to have a low risk of weight gain.
, , , et al
PCC
Original Research

Outcomes and Treatment Response in Schizophrenia

December 23, 2020

To better understand the burden of partial treatment response on schizophrenia patients, their caregivers, and health care resources, this study compared demographics, outcomes, and comorbidities among schizophrenia patients with...
, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe